MedElevator
Войти в исследования Human psychopharmacology · 2026
Tirzepatide Initiation in Lithium-Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real-World Cohort.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rescalli Maria Beatrice, Fagiolini Andrea, Carmellini Pietro, Pinzi Mario, Castaldo Flavia, Cuomo Alessandro
Аннотация
OBJECTIVE: To assess early renal and lithium-related safety and 12-month renal biomarker trajectories after tirzepatide initiation in lithium-treated adults with bipolar disorder.
METHODS: We retrospectively studied 23 adults at one centre. The principal 12-week renal safety measures were serum creatinine and derived CKD-EPI 2021 creatinine-based eGFR. Secondary outcomes included lithium, electrolytes, gastrointestinal symptoms, acute kidney injury meeting KDIGO creatinine criteria and discontinuation. Twelve-month trajectories and body-surface-area-unindexed eGFR were exploratory.
RESULTS: At 12 weeks, creatinine changed by -3 ± 12 μmol/L (p = 0.196), indexed eGFR by +2.6 ± 15.1 mL/min/1.73 m2 (p = 0.259) and lithium by +0.08 ± 0.17 mmol/L (p = 0.030). Among 20 on-treatment completers at 12 months, weight decreased by 17.7 ± 6.0%, creatinine by 12 ± 9 μmol/L, indexed eGFR increased by 13.0 ± 12.1 mL/min/1.73 m2 and unindexed eGFR by 4.5 ± 14.3 mL/min. Two patients had lithium > 1.2 mmol/L; one developed clinician-attributed symptomatic toxicity and discontinued tirzepatide. No acute kidney injury meeting KDIGO creatinine criteria could be confirmed from available records.
CONCLUSIONS: Co-prescription warrants structured monitoring and sick-day education. Creatinine-based eGFR changes during major weight loss do not establish renal benefit or exclude kidney injury.
METHODS: We retrospectively studied 23 adults at one centre. The principal 12-week renal safety measures were serum creatinine and derived CKD-EPI 2021 creatinine-based eGFR. Secondary outcomes included lithium, electrolytes, gastrointestinal symptoms, acute kidney injury meeting KDIGO creatinine criteria and discontinuation. Twelve-month trajectories and body-surface-area-unindexed eGFR were exploratory.
RESULTS: At 12 weeks, creatinine changed by -3 ± 12 μmol/L (p = 0.196), indexed eGFR by +2.6 ± 15.1 mL/min/1.73 m2 (p = 0.259) and lithium by +0.08 ± 0.17 mmol/L (p = 0.030). Among 20 on-treatment completers at 12 months, weight decreased by 17.7 ± 6.0%, creatinine by 12 ± 9 μmol/L, indexed eGFR increased by 13.0 ± 12.1 mL/min/1.73 m2 and unindexed eGFR by 4.5 ± 14.3 mL/min. Two patients had lithium > 1.2 mmol/L; one developed clinician-attributed symptomatic toxicity and discontinued tirzepatide. No acute kidney injury meeting KDIGO creatinine criteria could be confirmed from available records.
CONCLUSIONS: Co-prescription warrants structured monitoring and sick-day education. Creatinine-based eGFR changes during major weight loss do not establish renal benefit or exclude kidney injury.